Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611556 · ClinicalTrials.gov registry record · Phase 1
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT03611556: Completed Phase 1 study, sponsored by MedImmune.
NCT03611556 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 213 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (255% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03611556, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Durvalumab
- DRUG Oleclumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 1 |
What the finished NCT03611556 record still lists
NCT03611556 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (255% higher).
The record links to 0 conditions, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT03611556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03611556 about?
NCT03611556 is a clinical study titled "MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.". The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
What is the current status of trial NCT03611556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2018-06-21. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT03611556?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Durvalumab (DRUG), Oleclumab (DRUG).
Who is sponsoring clinical trial NCT03611556?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03611556's enrollment target sits among peer trials
213 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI